Bio-AMD Inc  

(Public, OTCMKTS:BIAD)   Watch this stock  
Find more results for OTC:BIAD
-0.006 (-2.69%)
Mar 27 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.19 - 0.26
52 week 0.02 - 0.30
Open 0.26
Vol / Avg. 231,304.00/225,355.00
Mkt cap 9.97M
P/E     -
Div/yield     -
EPS -0.02
Shares 44.53M
Beta -1.28
Inst. own 1%

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -91.10% -39.18%
Return on average equity -42.20% -26.10%
Employees 2 -
CDP Score - -


3rd Floor, 14 South Molton Street
United Kingdom - Map
+44-844-5862780 (Phone)

Website links


Bio-AMD, Inc. is engaged in the developing of point of care (POC) medical diagnostic reader device business and developing its currency risk mitigation business. Bio-AMD is a technology focused in the POC medical diagnostic reader market. Bio-AMD has three technologies namely digital strip reader (DSR), coagulation device (COAG) and magnetic particle reader (MPR). DSR performs a range of POC assay tests for infectious diseases, drugs of abuse, cardiology, oncology, cholesterol and the female well-being market (pregnancy, fertility and menopause). COAG is a micro-fluidic strip technology for use in POC hand-held device to detect prothrombin time (PT)/International Normalized Ratio (INR) or the coagulation of blood. COAG is also used for testing oral anticoagulation therapy. MPR provides measurement through the application of micro-fluidics and lab-on-chip technology.

Officers and directors

David S. Miller President, Secretary, Director
Age: 53
Thomas Barr Chief Executive Officer, Director
Age: 54
Robert Galvin Chief Financial Officer, Treasurer, Director
Age: 44